CC
NTGN

Casdin Capital’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Casdin Capital’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-263,344
Closed -$1.32M – 32
2018
Q4 		$1.32M Sell
263,344
-75,001
-22% -$525K 0.23% 31
2018
Q3 		$2.89M Hold
338,345
– – 0.35% 35
2018
Q2 		$4.26M Buy
+338,345
New +$4.63M 0.6% 28

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Casdin Capital's NTGN Position: Q1 2019 in Review

Casdin Capital sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q1 2019, closing a stake of 263,344 shares — an estimated $1.32M sold.

Casdin Capital first reported a position in NTGN in Q2 2018 and held it in 3 quarters. The position peaked at $4.26M in Q2 2018. 52 funds tracked by Wall St. Rank hold NTGN as of Q1 2019.

  • Casdin Capital reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Casdin Capital sold 263,344 Neon Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $1.32M.
  • Casdin Capital first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
  • Casdin Capital's Neon Therapeutics, Inc. Common Stock position peaked at $4.26M in Q2 2018.
  • 52 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Casdin Capital's 13F filing for Q1 2019, filed 15 May 2019.